Larissa de A. P. Ferreira

Discovery of First Quinoline–Acylguanidine Hybrids as Selective Butyrylcholinesterase Inhibitors: Design, Synthesis, and Molecular Basis

Alzheimer’s disease (DA) remains a major therapeutic challenge, and selective butyrylcholinesterase (BChE) inhibition has emerged as a promising strategy for symptomatic treatment, particularly in advanced stages. Herein, a series of novel quinoline–acylguanidine hybrids was designed through a bioisosteric replacement...